4 results
To compare the relative efficacy of sonothrombolysis in the acute management of STEMI following primary percutaneous coronary intervention [PCI] in patients with persistent ST elevation compared with standard of care.
* To assess the safety and tolerability of Ampligen administered intranasally in a dosing schedule for 13 days (7 doses) in healthy subjects.* To characterize the mucosal immune response following Ampligen administration over time.
Primary objectives: 1. Safety 2. Practical feasibility Secondary objectives: 1. angiographic patency rate before PCI 2. Cumulative ST-segment resolution. 3. myocardial infarct characteristics 4. Myocardial perfusion on contrast echocardiography 5.…
The primary objective of the safety run-in (phase Ib) is to determine the safety of combination therapy with durvalumab and rintatolimod. The primary objective of the phase II trial is to determine the clinical benefit rate of combination therapy…